Dopamine D4 receptors and the regulation of penile erection

Drug Discovery Today: Therapeutic Strategies

Volumn 3, Issue 4, 2006, Pages 599-604

  Brioni, Jorge D ^a   Moreland, Robert B ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 DIPROPYLAMINO 7 HYDROXYTETRALIN; 3 (4 PROPYLMORPHOLIN 2 YL)PHENOL; 3 [2 (4 CHLOROPHENYLTHIO)PHENYL] N (4 DIMETHYLAMINOBUTYL)ACRYLAMIDE; 3,4,4A,10B TETRAHYDRO 4 PROPYL 2H,5H [1]BENZOPYRANO[4,3 B][1,4]OXAZIN 9 OL; ABT 724; APOMORPHINE; BP 897; CLOZAPINE; CP 226269; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE 4 RECEPTOR; DOPAMINE 4 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; PD 168077; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PNU 142774E; PRAMIPEXOLE; PROSTAGLANDIN E1; QUINPIROLE; SILDENAFIL; SPIPERONE; SUMANIROLE; TADALAFIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VARDENAFIL;

BACKACHE; CLINICAL TRIAL; DIZZINESS; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DEPENDENCE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; DYSPEPSIA; ERECTILE DYSFUNCTION; FLUSHING; HUMAN; LOW DRUG DOSE; NONHUMAN; NOSE CONGESTION; PARKINSON DISEASE; PENIS ERECTION; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RESTLESS LEGS SYNDROME; REVIEW; SIDE EFFECT; THALAMUS MIDLINE NUCLEUS; VISUAL DISORDER;

EID: 33846131545     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2006.10.006     Document Type: Review

References (32)

1. Wespes E., et al. EAU guidelines on erectile dysfunction: an update. Eur. Urol. 49 (2006) 806-815
2. Cirino G., et al. Pharmacology of erectile dysfunction in man. Pharmacol. Ther. 111 (2006) 400-423
3. Moreland R.B., et al. Prospectives for pharmacotherapy for male erectile dysfunction. Curr. Opin. CPNS Invest. Drugs 2 (2000) 283-302
4. Kebabian J., and Calne D. Multiple receptors for dopamine. Nature 277 (1979) 93-96
5. Missale C., et al. Dopamine receptors: from structure to function. Physiol. Rev. 78 (1998) 189-225
6. Primus R., et al. II. Localization and characterization of dopamine D4 binding sites in rat and human brain by use of the novel, D4 receptor-selective ligand [3H]NGD 94-1. J. Pharmacol. Exp. Ther. 282 (1997) 1020-1027
7. Meador-Woodruff J., et al. Dopamine receptor mRNA expression in human striatum and neocortex. Neuropsychopharmacology 15 (1996) 17-29
8. Ariano M., et al. Cellular distribution of the rat D4 dopamine receptor protein in the CNS using anti-receptor antisera. Brain Res. 752 (1997) 26-34
9. Khan Z., et al. Differential regional and cellular distribution of dopamine D2-like receptors: an immunocytochemical study of subtype-specific antibodies in rat and human brain. J. Comp. Neurol. 402 (1998) 353-371
10. 4 receptor agonists for treating sexual dysfunction. WO02/41894A2
11. qo5. Biochem. Pharmacol. 68 (2004) 761-772
12. 4 receptor: one decade of research. Eur. J. Pharmacol. 405 (2000) 303-327
13. Hsieh G., et al. Central mechanisms regulating penile erection in conscious rats: the dopaminergic systems related to the proerectile effect of apomorphine. J. Pharmacol. Exp. Ther. 308 (2004) 330-338
14. Lal S., et al. Apomorphine-induced penile tumescence in impotent patients-preliminary findings. Progr. Neuro-Psychopharmacol. Biol. Psychiatry 11 (1987) 235-242
15. Dula E., et al. Efficacy and safety of fixed-dose and dose-optimization regimens of sublingual apomorphine versus placebo in men with erectile dysfunction. The Apomorphine Study Group. Urology 56 (2000) 130-135
16. 4, receptor agonists are emetogenic in ferrets. Pharmacol. Biochem. Behav. 81 (2005) 211-219
17. 3 receptor agonist. Nature 400 (1999) 371-375
18. 3 receptor. Eur. J. Pharmacol. 407 (2000) 47-51
19. 2 agonist binding for determination of receptor subtype selectivity. J. Med. Chem. 39 (1996) 4233-4237
20. 4 receptor. Eur. J. Pharmacol. 497 (2004) 147-154
21. 2/3 receptor agonists for treating sexual dysfunction. WO03/051370A1
22. 4 receptors by ABT-724 induces penile erection in rats. Proc. Natl. Acad. Sci. U S A 101 (2004) 6758-6763
23. 4 ligands and models of receptor activation: 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole and related heteroarylmethylarylpiperazines exhibit a substituent effect responsible for additional efficacy tuning. J. Med. Chem. 47 (2004) 2348-2355
24. Cowart M., et al. Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunction. J. Med. Chem. 47 (2004) 3853-3864
25. 4 receptor agonists. Biorg. Med. Chem. Lett. 12 (2004) 3471-3483
26. 4 receptor agonist, induces penile erection when injected into the paraventricular nucleus of male rats. Neurosci. Lett. 379 (2005) 59-62
27. 4 receptor signaling in the rat paraventricular hypothalamic nucleus: evidence of natural coupling involving immediate early gene induction and mitogen activated protein kinase phosphorylation. Neuropharmacology 50 (2006) 521-531
28. Fourcroy J.L. Female sexual dysfunction: potential for pharmacotherapy. Drugs 63 (2003) 1445-1457
29. Brioni J., et al. Activators of soluble guanylate cyclase for the treatment of male erectile dysfunction. Int. J. Impot. Res. 14 (2002) 8-14
30. Moreland R.B., et al. Emerging pharmacologic approaches for the treatment of lower urinary tract disorders. J. Pharmacol. Exp. Ther. 308 (2004) 797-804
31. Moreland R.B., et al. The biochemical and neurologic basis for treatment of male erectile dysfunction. J. Pharmacol. Exp. Ther. 296 (2001) 225-234
32. Montorsi F., et al. Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies. Urology 53 (1999) 1011-1018